Mehdi Shamsara

AUG 3, 2026 · JOURNAL ARTICLE

T cell engineering by targeted small extracellular vesicles delivering CRISPR/Cas9 system for PD-1 knock-out

Applied Microbiology and Biotechnology

First-in-kind proof-of-concept study demonstrating a novel delivery mechanism in vitro; no animal or clinical data, no comparative efficacy trial, and no hard clinical endpoints reported.